GlassScriptPhysician profile
Jasmine Crystal Smith
NPI 1902492283
$4,653.10
in general payments reported to CMS, 2019-2025
46 companies · $97.13 in 2025
The $97.13 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $1,469 · 2023: $1,722 · 2024: $944 · 2025: $97.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Consulting Fee: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.80 |
| Consulting Fee | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,048.90 | 2023-2024 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $645.32 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $309.86 | 2021-2023 | Enhertu, Andexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $223.65 | 2021-2024 | Fruzaqla, Hyqvia, Vonvendi |
| Amgen INC. | $214.15 | 2021-2024 | Evenity |
| Eisai INC. | $202.05 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $144.58 | 2021-2022 | |
| Seagen INC. | $141.25 | 2021-2023 | Tukysa, Adcetris |
| Jazz Pharmaceuticals INC. | $135.40 | 2022 | |
| Sobi, INC | $119.64 | 2022-2024 | |
| Daiichi Sankyo INC. | $110.38 | 2024-2025 | Injectafer, Enhertu |
| Abbvie INC. | $107.58 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $100.70 | 2021-2024 | Opdivo |
| Janssen Biotech, INC. | $93.46 | 2023-2024 | Imbruvica, Carvykti, Darzalex |
| Gilead Sciences, INC. | $85.51 | 2022-2024 | Trodelvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.